TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy: EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy— EGFR mutated non-small cell lung cancer IV patients treated with osimertinib

Saved in:

Bibliographic Details
Main Authors:	Roeper, Julia (Author) , Christopoulos, Petros (Author) , Falk, Markus (Author) , Heukamp, Lukas (Author) , Tiemann, Markus (Author) , Stenzinger, Albrecht (Author) , Thomas, Michael (Author) , Griesinger, Frank (Author)
Format:	Article (Journal)
Language:	English
Published:	January 2022
In:	Translational Lung Cancer Research Year: 2022, Volume: 11, Issue: 1, Pages: 4-16
ISSN:	2226-4477
DOI:	10.21037/tlcr-21-754
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.21037/tlcr-21-754 Verlag, lizenzpflichtig, Volltext: https://tlcr.amegroups.com/article/view/60522 Resolving-System, kostenfrei: https://doi.org/10.21037/tlcr-21-754
Author Notes:	Julia Roeper, Petros Christopoulos, Markus Falk, Lukas C. Heukamp, Markus Tiemann, Albrecht Stenzinger, Michael Thomas, Frank Griesinger

Description
Summary:	TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy— EGFR mutated non-small cell lung cancer IV patients treated with osimertinib
Item Description:	Gesehen am 14.02.2022
Physical Description:	Online Resource
ISSN:	2226-4477
DOI:	10.21037/tlcr-21-754